In PSUMMIT 1 and 2, patients with PsA were randomized to placebo or ustekinumab 45 mg or 90 mg. Enthesitis was assessed at weeks 0 and 24 (Maastricht Ankylosing SpondylitisEnthesitis Score).
Among patients with baseline enthesitis and dactylitis, 62.4% achieved a Maastricht Ankylosing SpondylitisEnthesitis Score of 0 and 80.9% achieved a dactylitis count of 0, respectively.
A variety of clinical indices exist to assess enthesitis in PsA; however, the Leeds Enthesitis Index and Maastricht Ankylosing SpondylitisEnthesitis Score index have been the most frequently used indices in recent clinical trials.